Incannex Healthcare
A clinical stage pharmaceutical company developing proprietary medicinal cannabinoid drugs and psychedelic medicine therapies.
Incannex' key drug candidates are aimed at treating obstructive sleep apnoea (OSA), rheumatoid arthritis, inflammatory bowel disease, lung inflammation (ARDS, COPD, asthma, bronchitis), traumatic brain injury (TBI) and concussion, anxiety disorders, addiction disorders, and pain, among other indications.
As of Q4 2024, Incannex is pursuing FDA registration and marketing approval for each product and therapy under development. Incannex also has a strong patent filing strategy, holding 19 granted patents and 30 pending patent applications over its portfolio of R&D programs.
Latest Incannex Healthcare News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze